Abstract
No public abstract is available from the verified source records.
Jinyi Yuan, Xiaoju Zhang, Hua Zhu, Paurus Irani, Junchao Lu, Fanglei Liu, Yuting Mu, Haihui Huang, Yingyuan Zhang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
10.3389/fcimb.2022.823684 · 2022
Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review
2021
Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy
10.1016/j.micres.2022.127249 · 2023
Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: A systematic analysis from the MICROBE database
10.1016/j.ijid.2024.107769 · 2025
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
WHO Bacterial Priority Pathogens List, 2024
2024
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme
10.1093/jac/dkad280 · 2023
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
10.1093/jac/dky204 · 2018
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
10.1007/s40121-021-00507-6 · 2021
Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis
10.1007/s40121-024-00999-y · 2024
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
10.1016/s1473-3099(17)30747-8 · 2018
Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points
10.1093/ofid/ofz149 · 2019
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
10.1093/cid/ciw133 · 2016
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
10.1093/cid/ciw378 · 2016
10.1016/s1473-3099(16)30004-4
10.1016/s1473-3099(16)30004-4 · 2016
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
10.1016/j.ijantimicag.2017.01.010 · 2017
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
10.1016/j.jmii.2023.01.017 · 2023
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms
10.1016/j.jmii.2022.02.001 · 2022
Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China
10.3389/fcimb.2020.00314 · 2020
Interval estimation for a binomial proportion
10.1214/ss/1009213286 · 2001
One-sided confidence intervals in discrete distributions
10.1016/j.jspi.2004.01.005 · 2005
Comparative analysis of two rates
10.1002/sim.4780040211 · 1985
The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study
10.1007/s40121-023-00762-9 · 2023
Ceftazidime-avibactam: effectiveness and safety in the clinical practice. A third hospital level experience
2022
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
10.1093/ofid/ofz522 · 2019
Analysis of the clinical application of ceftazidime-avibactam in China
10.1016/j.jiph.2022.02.003 · 2022
No additional external references are available.